Clinical Trial Update: Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome [Phase 4]

View source ↗

Summary

The document reports a Phase 4 clinical trial update from Novartis focused on reducing overall cardiovascular risk in patients with metabolic syndrome, includin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypertension
• Metabolic Syndrome

Snippet

Sponsor: Novartis | Conditions: Hypertension, Dyslypidaemia | Phase 4 | Status: COMPLETED